LLY vs PFE
Eli Lilly · Pfizer
| LLY Eli Lilly Healthcare | PFE Pfizer Healthcare | |
|---|---|---|
| Market | ||
| Price | $1,417.54 +3.19% | $30.52 +1.90% |
| Market cap | $1.33T | $174.0B |
| P/E (TTM) | 48.4 | 40.1 |
| Dividend yield | 0.75% | 5.38% |
| 52-week range | $809.63 – $1,408.38 | $23.62 – $30.67 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Eli Lilly (LLY): Two Drugs Drove 88% Of Growth, EPS Hit By $4.57 R&D Oct 31, 2026 | Pfizer's Vyndaqel Patent Cliff Just Got Pushed To 2031 — The Market Hasn't Noticed Yet (P… Jun 14, 2026 |
| Latest earnings | ||
| Reported | Oct 29, 2026 | — |
| Revenue | $24.4 billion +39% YoY | — |
| EPS | $7.22 +7% YoY | — |
| Guidance | Guidance raised | — |
| Revenue growth, last 4 reports | +39% +48% | — |
| Topics | ||
| Main topics | ||
| Company page · Earnings releases | Company page | |
Shared topics: GLP-1 Mergers & Acquisitions
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.